Mechanisms that Promote Chronic Lung Transplant Rejection
促进慢性肺移植排斥的机制
基本信息
- 批准号:10024446
- 负责人:
- 金额:$ 39.36万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-05-12 至 2025-05-31
- 项目状态:未结题
- 来源:
- 关键词:AblationAdoptive TransferAllograft ToleranceAllograftingAlveolar MacrophagesAntibodiesAutoantigensAutoimmune DiseasesBone Marrow TransplantationBronchiolitisBronchiolitis ObliteransCD8-Positive T-LymphocytesCD8B1 geneCSF3 geneCell ProliferationCell SurvivalCellsChromatinChronicClinicalCommunicationCoupledDataDendritic CellsDevelopmentDiseaseExposure toFoundationsFunctional disorderGastroesophageal reflux diseaseGene TargetingGenerationsGenesGraft RejectionGranulocyte-Macrophage Colony-Stimulating FactorITGAX geneImmuneImmunologicsImpairmentInfectionInflammatoryInterferon Type IIschemiaJointsLaboratoriesLeftLesionLifeLongevityLungLung TransplantationLung diseasesMHC Class I GenesMaintenanceMediatingMediator of activation proteinMethodsModelingMusNatural Killer CellsOperative Surgical ProceduresOrganOrgan TransplantationOutcome StudyPathogenesisPathologicPathway interactionsPatientsPlayPreventionProcessRegimenRegulationReperfusion InjuryReperfusion TherapyReportingRiskRisk FactorsRoleShapesSolidStressSyndromeT cell responseT-Lymphocyte SubsetsTechniquesToxic Environmental SubstancesTransforming Growth Factor betaTransplantationTransplantation Toleranceadaptive immune responseairway epitheliumautoreactivitybasecell regenerationcytotoxic CD8 T cellseffector T cellepithelial injuryepithelial stem cellextracellularfunctional lossimprovedinnovationlung allograftmacrophagemonocyteneutrophilnovelnovel strategiespathogenpreventprogenitorrepairedresponsetraffickingtransplant modeltreatment strategy
项目摘要
PROJECT SUMMARY/ABSTRACT
Lung recipients suffer from shorter life spans and higher rejection rates when compared to other solid organ
recipients. Bronchiolitis obliterans syndrome (BOS) is the most common cause of chronic lung transplant
rejection. Based on clinical outcome studies that have identified many known non-alloimmune mediators of
epithelial injury as risk factors for BOS, we have developed a new mouse orthotopic lung transplant model that
recapitulates this relationship. This innovation has allowed us to a identify a key airway epithelial cell progenitor,
the club cell, as vital for the maintenance of allograft tolerance and the prevention of obliterative bronchiolitis
(OB) - the major pathological indicator of BOS. We have also observed that OB is driven by graft-infiltrating
effector CD8+ T cells that inhibit club cell-mediated repair of airway epithelium. New data from our laboratory
suggests that follicular cytotoxic CD8+ T cells, a poorly defined CD8+ T cell subset with no reported role in solid
organ transplantation, may facilitate responses against pulmonary-self antigens. Our group has previously
reported that CCR2+ monocytes (CM) and neutrophil extracellular traps (NETs) play critical roles in both lung
transplant ischemia-reperfusion injury and the induction of lung allograft tolerance, but their role in the
maintenance of tolerance remains unclear. We have now uncovered evidence implicating graft-infiltrating CM
and NETs in OB pathogenesis. Here we propose to dissect the mechanisms by which CM (Aim 1), effector
CD8+ T cells (Aim 2) and NETs (Aim 3) promote OB pathogenesis. We will also examine how CM and NETs
shape effector CD8+ T cell responses that promote OB pathogenesis. Through these studies, we expect to
reveal targetable pathways that promote BOS.
项目总结/摘要
与其他实体器官相比,肺受体的寿命较短,排斥率较高
受惠人士闭塞性细支气管炎综合征(BOS)是慢性肺移植最常见的原因
排斥反应基于临床结果研究,已经确定了许多已知的非同种免疫介质,
上皮损伤作为BOS的危险因素,我们已经开发了一种新的小鼠原位肺移植模型,
概括了这种关系。这项创新使我们能够鉴定出一种关键的气道上皮细胞祖细胞,
俱乐部细胞对于维持同种异体移植物耐受性和预防闭塞性细支气管炎至关重要
(OB)- BOS的主要病理指标。我们还观察到OB是由移植物浸润
抑制棒状细胞介导的气道上皮修复的效应CD 8 + T细胞。我们实验室的新数据
提示滤泡细胞毒性CD 8 + T细胞,一种定义不明确的CD 8 + T细胞亚群,在实体瘤中没有报道作用,
器官移植可以促进针对肺自身抗原的应答。我们的团队以前
报道CCR 2+单核细胞(CM)和中性粒细胞胞外陷阱(NET)在两个肺中起关键作用,
移植物缺血-再灌注损伤和诱导肺移植耐受,但它们的作用,
耐受性的维持仍不清楚。我们现在发现的证据表明移植物渗入CM
NET在OB发病机制中的作用。在这里,我们建议剖析CM(目标1),效应器
CD 8 + T细胞(Aim 2)和NET(Aim 3)促进OB发病。我们还将研究CM和NET如何
形成效应CD 8 + T细胞反应,促进OB发病机制。通过这些研究,我们希望
揭示促进BOS的靶向途径。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Andrew Eric Gelman其他文献
Andrew Eric Gelman的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Andrew Eric Gelman', 18)}}的其他基金
PET Tracer for Imaging of Lung Inflammation
用于肺部炎症成像的 PET 示踪剂
- 批准号:
10682270 - 财政年份:2023
- 资助金额:
$ 39.36万 - 项目类别:
Mechanisms that Promote Chronic Lung Transplant Rejection
促进慢性肺移植排斥的机制
- 批准号:
10619069 - 财政年份:2015
- 资助金额:
$ 39.36万 - 项目类别:
Mechanisms that Promote Chronic Lung Transplant Rejection
促进慢性肺移植排斥的机制
- 批准号:
10197019 - 财政年份:2015
- 资助金额:
$ 39.36万 - 项目类别:
Mechanisms that Promote Chronic Lung Transplant Rejection
促进慢性肺移植排斥的机制
- 批准号:
10625538 - 财政年份:2015
- 资助金额:
$ 39.36万 - 项目类别:
MECHANISMS OF EXTRACORPOREAL PHOTOPHERESIS IN THE TREATMENT OF LUNG ALLOGRAFT REJECTION
体外光采术治疗同种异体肺排斥反应的机制
- 批准号:
9056994 - 财政年份:2015
- 资助金额:
$ 39.36万 - 项目类别:
GRANULOPOIESIS REGULATION IN LUNG GRAFT ISCHEMIA-REPERFUSION INJURY
肺移植物缺血再灌注损伤中的粒细胞生成调节
- 批准号:
8666608 - 财政年份:2013
- 资助金额:
$ 39.36万 - 项目类别:
相似海外基金
Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
ATTAC 时间:针对 gp100 细胞的 T 细胞过继转移来治疗 LAM
- 批准号:
10682121 - 财政年份:2023
- 资助金额:
$ 39.36万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10576370 - 财政年份:2022
- 资助金额:
$ 39.36万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10387023 - 财政年份:2022
- 资助金额:
$ 39.36万 - 项目类别:
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10248409 - 财政年份:2019
- 资助金额:
$ 39.36万 - 项目类别:
A phase I clinical study of adoptive transfer of regulatory T cells (Tregs) and low-dose interleukin-2 (IL-2) for the treatment of chronic graft-versus-host disease (GVHD): gene-marking to inform rational combination therapy
调节性 T 细胞 (Treg) 和低剂量白细胞介素 2 (IL-2) 过继转移治疗慢性移植物抗宿主病 (GVHD) 的 I 期临床研究:基因标记为合理的联合治疗提供信息
- 批准号:
nhmrc : GNT1163111 - 财政年份:2019
- 资助金额:
$ 39.36万 - 项目类别:
Project Grants
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10462684 - 财政年份:2019
- 资助金额:
$ 39.36万 - 项目类别:
Gene edited lymphoid progenitors for adoptive transfer as a treatment of primary immunodeficiency
基因编辑的淋巴祖细胞用于过继转移作为原发性免疫缺陷的治疗
- 批准号:
398018062 - 财政年份:2018
- 资助金额:
$ 39.36万 - 项目类别:
Research Grants
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9308643 - 财政年份:2017
- 资助金额:
$ 39.36万 - 项目类别:
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9447149 - 财政年份:2017
- 资助金额:
$ 39.36万 - 项目类别:
Targeting Cancer miRNAs by Adoptive Transfer of Programmed B Lymphocytes
通过程序化 B 淋巴细胞的过继转移靶向癌症 miRNA
- 批准号:
8893915 - 财政年份:2014
- 资助金额:
$ 39.36万 - 项目类别:














{{item.name}}会员




